- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
Brand Name :
Inspra
Synonyms :
eplerenone
Class :
Potassium-sparing diuretics, Aldosterone receptor antagonists
Dosage Forms & Strengths
Tablet
25mg
50mg
50
mg
Orally
daily
; may increase the dose up to 50 mg
congestive Heart Failure (CHF)
25
mg
Orally
daily
25
mg
Orally
every day
may decrease the antihypertensive effect of nonsteroidal anti-inflammatory agents
may decrease the antihypertensive effect of nonsteroidal anti-inflammatory agents
may decrease the antihypertensive effect of nonsteroidal anti-inflammatory agents
may decrease the antihypertensive effect of nonsteroidal anti-inflammatory agents
may decrease the antihypertensive effect of nonsteroidal anti-inflammatory agents
may enhance the concentration of serum when combined with eplerenone
may enhance the concentration of serum when combined with eplerenone
may enhance the concentration of serum when combined with eplerenone
may enhance the concentration of serum when combined with eplerenone
may enhance the concentration of serum when combined with eplerenone
eplerenone: they may enhance the serum concentration of CYP3A Inhibitors
eplerenone: they may enhance the serum concentration of CYP3A Inhibitors
eplerenone: they may enhance the serum concentration of CYP3A Inhibitors
eplerenone: they may enhance the serum concentration of CYP3A Inhibitors
eplerenone: they may enhance the serum concentration of CYP3A Inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the potassium levels in the blood when combined with sparsentan.
CYP3A strong enhancers of the small intestine may reduce the bioavailability of eplerenone
may enhance the serum concentration of CYP3A4 inhibitors
angiotensin II Receptor Blockers may enhance the hyperkalemic effect of potassium-Sparing Diuretics
angiotensin II Receptor Blockers may enhance the hyperkalemic effect of potassium-Sparing Diuretics
angiotensin II Receptor Blockers may enhance the hyperkalemic effect of potassium-Sparing Diuretics
angiotensin II Receptor Blockers may enhance the hyperkalemic effect of potassium-Sparing Diuretics
angiotensin II Receptor Blockers may enhance the hyperkalemic effect of potassium-Sparing Diuretics
may enhance the hyperkalemic effect of ACE Inhibitors
may enhance the hyperkalemic effect of ACE Inhibitors
may enhance the hyperkalemic effect of ACE Inhibitors
may enhance the hyperkalemic effect of ACE Inhibitors
may enhance the hyperkalemic effect of ACE Inhibitors
may enhance the hyperkalemic effect of ACE Inhibitors
may enhance the hyperkalemic effect of ACE Inhibitors
may enhance the hyperkalemic effect of ACE Inhibitors
may enhance the hyperkalemic effect of ACE Inhibitors
may enhance the hyperkalemic effect of ACE Inhibitors
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
may increase the hyperkalemic effect of ACE Inhibitors
may increase the hyperkalemic effect of ACE Inhibitors
may increase the hyperkalemic effect of ACE Inhibitors
may increase the hyperkalemic effect of ACE Inhibitors
may increase the hyperkalemic effect of ACE Inhibitors
nitrofurantoin has the potential to amplify the hyperkalemic effect of eplerenone
eplerenone: they may increase the hyperkalemic effect of Angiotensin II Receptor antagonist
eplerenone: they may increase the hyperkalemic effect of Angiotensin II Receptor antagonist
eplerenone: they may increase the hyperkalemic effect of Angiotensin II Receptor antagonist
eplerenone: they may increase the hyperkalemic effect of Angiotensin II Receptor antagonist
eplerenone: they may increase the hyperkalemic effect of Angiotensin II Receptor antagonist
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
the effect of eplerenone is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
NSAIDsmay diminish the antihypertensive effect of Potassium-Sparing Diuretics
NSAIDsmay diminish the antihypertensive effect of Potassium-Sparing Diuretics
NSAIDsmay diminish the antihypertensive effect of Potassium-Sparing Diuretics
NSAIDsmay diminish the antihypertensive effect of Potassium-Sparing Diuretics
NSAIDsmay diminish the antihypertensive effect of Potassium-Sparing Diuretics
may increase the hyperkalemic effect of diuretics
may increase the anti-coagulant action of anti-coagulants
may increase the hyperkalemic effect of angiotensin receptor II blockers
may increase the toxic effect of angiotensin receptor II blockers
may decrease the anti-hypertensive effect of nonsteroidal anti-inflammatory agents
may increase the hyperkalemic effect when combined with potassium-sparing diuretics
may have an increased hyperkalemic effect when combined with eplerenone
may have an increased hyperkalemic effect when combined with potassium-sparing diuretics
drospirenone/ethinyl estradiol/levomefolate
may increase the hyperkalemic effect of Drospirenone-Containing Products
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
trimethoprim: they may increase the hyperkalemic effect of eplerenone
Angiotensin II Receptor Blockers: they may increase the hyperkalemic effect of potassium-sparing diuretics
Angiotensin II Receptor Blockers: they may increase the hyperkalemic effect of potassium-sparing diuretics
Angiotensin II Receptor Blockers: they may increase the hyperkalemic effect of potassium-sparing diuretics
Angiotensin II Receptor Blockers: they may increase the hyperkalemic effect of potassium-sparing diuretics
Angiotensin II Receptor Blockers: they may increase the hyperkalemic effect of potassium-sparing diuretics
may enhance the hyperkalemic effect
may enhance the hyperkalemic effect
may enhance the hyperkalemic effect
it enhances the effect of hyperkalemia in potassium salts
Adverse drug reactions
Frequency Defined
1-10%
Hyperkalemia (2-10%)
1-3%
Abdominal pain
Albuminuria
Cough
Diarrhea
Dizziness
Hypercholesterolemia
Fatigue/malaise
Hypertriglyceridemia
<1%
Mastodynia
Gynecomastia
Abnormal vaginal bleeding
Pregnancy warnings:
AU TGA pregnancy category: B3
US FDA pregnancy category: Not assigned
Lactation:
Excreted into human milk is unknown
Pregnancy Categories:
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first or later trimester.
Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant women
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Patient Information Leaflet
Generic Name: eplerenone
Why do we use eplerenone?
eplerenone is an Aldosterone receptor antagonists used to treat Post MI and CHF.
ADVERTISEMENT
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
